The Program for Pulmonary Fibrosis and Interstitial Lung Disease's mission is to provide state of the art evaluation and treatment for patients with interstitial lung diseases (ILD). The University of ...
The following is a summary of “Progressive Early Interstitial Lung Abnormalities in Persons at Risk for Familial Pulmonary ...
LCI proves valuable in monitoring ETI therapy effectiveness for cystic fibrosis patients with minimal FEV1 changes, detecting ...
News Medical on MSN14d
Dextromethorphan found to have potential in treating lung fibrosisA common over-the-counter ingredient in many cough syrups may have a greater purpose for people suffering from lung fibrosis that is related to any number of serious health conditions. A new study has ...
Cereno's expanded access program for investigational therapy CS1 covers 10 PAH patients, following a Phase 2a clinical trial.
assessing the efficacy and safety of ENV-101 (taladegib), an investigational drug for treating idiopathic pulmonary fibrosis (IPF). The Phase IIb ‘Wound-remodeling Hedgehog-Inhibitor ILD Study ...
A common over-the-counter ingredient in many cough syrups may have a greater purpose for people suffering from lung fibrosis that is related to any number of serious health conditions. Scientists ...
The Program for Pulmonary Fibrosis and Interstitial Lung Disease's mission is to provide state of the art evaluation and treatment for patients with interstitial lung diseases (ILD). The University of ...
The placebo-controlled, double-blind ‘Wound-remodeling Hedgehog-Inhibitor ... and its effects on lung capacity and fibrosis, as measured by chest high-resolution computed tomography (HRCT).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback